Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000)

被引：0
|
作者：
Carlile, David [1 ]
Meneses-Lorente, Georgina [1 ]
Wassner-Fritsch, Elisabeth [2 ]
Hourcade-Potelleret, Florence [1 ]
Wenger, Michael K. [2 ]
Cartron, Guillaume [3 ]
Vitolo, Umberto [5 ]
Radford, John [4 ]
Davies, Andrew [6 ]
Morschhauser, Franck [7 ]
机构：
[1] Roche Prod Ltd, Clin Pharmacol, Welwyn Garden City AL7 3AY, Herts, England
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Hop St Eloi, Serv Hematol Oncol Med, Montpellier, France
[4] Christie NHS Fdn Trust, Manchester, Lancs, England
[5] AO San Giovanni Battista, Hematol, Turin, Italy
[6] Canc Sci Div, Southampton, Hants, England
[7] CHU Lille, F-59037 Lille, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1582 / 1583
页数：2
相关论文
共 36 条
  • [1] Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
    Radford, John
    Davies, Andrew
    Cartron, Guillaume
    Morschhauser, Franck
    Salles, Gilles
    Marcus, Robert
    Wenger, Michael
    Lei, Guiyuan
    Wassner-Fritsch, Elisabeth
    Vitolo, Umberto
    BLOOD, 2013, 122 (07) : 1137 - 1143
  • [2] Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)
    Radford, John
    Davies, Andrew
    Cartron, Guillaume
    Morschhauser, Franck
    Salles, Gilles Andre
    Marcus, Robert E.
    Wenger, Michael K.
    Asikanius, Elina
    Wassner-Fritsch, Elisabeth
    Vitolo, Umberto
    BLOOD, 2011, 118 (21) : 124 - 125
  • [3] Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)
    Davies, Andrew
    Radford, John
    Cartron, Guillaume
    Morschhauser, Franck
    Salles, Gilles Andre
    Marcus, Robert
    Wenger, Michael K.
    Lei, Guiyuan
    Wassner-Fritsch, Elisabeth
    Vitolo, Umberto
    BLOOD, 2013, 122 (21)
  • [4] Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999)
    Meneses-Lorente, Georgina
    Carlile, David
    Birkett, Joe
    Wenger, Michael K.
    Cartron, Guillaume
    Morschhauser, Franck
    Salles, Gilles Andre
    BLOOD, 2010, 116 (21) : 765 - 765
  • [5] Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)
    Dyer, Martin J. S.
    Grigg, Andrew
    Gonzalez, Marcos
    Dreyling, Martin
    Rule, Simon A.
    Lei, Guiyuan
    Wassner-Fritsch, Elisabeth
    Wenger, Michael K.
    Marlton, Paula
    BLOOD, 2012, 120 (21)
  • [6] A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease
    Salles, Gilles Andre
    Morschhauser, Franck
    Cartron, Guillaume
    Lamy, Thierry
    Milpied, Noel-Jean
    Thieblemont, Catherine
    Tilly, Herve
    Birkett, Joe
    Burgess, Mike
    BLOOD, 2008, 112 (11) : 93 - 93
  • [7] A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease
    Sehn, Laurie H.
    Assouline, Sarit E.
    Stewart, Douglas A.
    Mangel, Joy
    Pisa, Pavel
    Kothari, Jaimal
    Crump, Michael
    BLOOD, 2009, 114 (22) : 385 - 385
  • [8] Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Uchida, Toshiki
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Mori, Masakazu
    Terui, Yasuhito
    Yokoyama, Masahiro
    Hotta, Tomomitsu
    CANCER SCIENCE, 2013, 104 (01) : 105 - 110
  • [9] Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
    Salles, Gilles A.
    Morschhauser, Franck
    Solal-Celigny, Philippe
    Thieblemont, Catherine
    Lamy, Thierry
    Tilly, Herve
    Gyan, Emmanuel
    Lei, Guiyuan
    Wenger, Michael
    Wassner-Fritsch, Elisabeth
    Cartron, Guillaume
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2920 - +
  • [10] Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+Non-Hodgkin Lymphoma (NHL).
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Carlile, David
    Cartron, Guillaume
    BLOOD, 2009, 114 (22) : 679 - 679
1234